The US Food and Drug Administration has approved Stivarga (regorafenib), a multi-kinase inhibitor, to treat patients with metastatic colorectal cancer. Developed by Bayer AG, the drug was approved under the agency’s priority review procedure. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
